Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-human NGF antibody, preparation method and use thereof

An antibody and antigen technology, applied in the fields of botanical equipment and methods, biochemical equipment and methods, antibodies, etc., can solve the problems of different immunogenicity, affecting drug efficacy, antibody tolerance speed and toxicity.

Active Publication Date: 2019-06-25
AMPSOURCE BIOPHARMA (SHANGHAI) INC +1
View PDF14 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The immunogenicity of different CDRs is different, resulting in different antibody tolerance speed and toxicity, which directly affects the efficacy of the drug
On the other hand, the subject's immune response to the antibody itself will form immune complexes, which will alter the pharmacokinetics and produce allergic reactions, etc., eliminating its therapeutic use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-human NGF antibody, preparation method and use thereof
  • Anti-human NGF antibody, preparation method and use thereof
  • Anti-human NGF antibody, preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0047] Abbreviations and Definitions

[0048] hNGF human nerve growth factor

[0049] CDR Complementarity-determining region in the variable region of an immunoglobulin defined by the IMGT numbering system

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an antibody or an antigen-binding fragment thereof that binds to NGF, and lists amino acid sequences of the heavy and light chain variable regions of the antibody. The NGF antibody or the antigen-binding fragment thereof provided by the invention has high affinity for NGF, and can effectively block the binding between the NGF receptor and NGF. The antibody or the antigen-binding fragment thereof inhibits the binding activity of NGF and the receptor in vitro, and is suitable for treating pain diseases associated with expression hyperfunction and elevated levels ofNGF.

Description

technical field [0001] The present invention relates to the field of therapeutic monoclonal antibodies, more specifically, to an anti-NGF antibody or an antigen-binding fragment thereof and uses thereof. Background technique [0002] Nerve growth factor (Never Growth Factor, NGF) is the first discovered neurotrophic factor, it has dual biological functions of neuron nutrition and neurite growth, and it has a great influence on the development, differentiation, growth, regeneration and function of central and peripheral neurons. The expression of traits all play an important regulatory role. NGF contains three subunits of α, β and γ, and the β subunit is the active subunit of NGF to play the role of nerve regeneration and repair. Currently known NGF receptors include high-affinity tyrosine kinase receptor (Tropomyosin receptor kinase A, TrkA) and low-affinity p75 neurotrophin receptor (p75Neurotrophin Receptor, p75NTR). [0003] Although the primary role of NGF was to promo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/22C12N15/13A61K39/395A61P29/00A61P19/02A61P13/10A61P19/08A61P25/02
CPCC07K16/22C12N15/85C12N5/0682A61P19/02A61P29/00A61P13/10A61P19/08A61P3/10A61P25/02C07K2317/565C07K2317/56C07K2317/24C07K2317/567C07K2317/76C12N2800/107C12N2510/00A61K2039/505
Inventor 王著高永娟陈思周若芸郑云程孙乃超李强
Owner AMPSOURCE BIOPHARMA (SHANGHAI) INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products